You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The researchers also plan to analyze how payors make coverage decisions for NGS-based gene panels, exome, and whole-genome sequencing clinical tests.
The positive coverage determination is one of several the company has received in recent months from various insurance companies for the ConfirmMDx test.
The in-network agreement gives the health plan's 8 million members access to Trovagene's full menu of liquid biopsy tests.
At HudsonAlpha's Genomic Medicine Conference University of North Carolina's Anya Prince discussed insurance coverage of genetic tests and preventive care.
MDxHealth said the positive medical policy decision adds to growing recognition of the ConfirmMDx test's value for improving patient outcomes.
While undergoing parallel review for its FoundationOne test by the FDA and CMS, the firm will continue to work with its local MACs on reimbursement.
The insurer will cover Metamark's urology specialized diagnostics throughout the state.
The blood-based test will be covered by one of the largest health plans in the state of Michigan.
The deal is the latest coverage and reimbursement success for the Cambridge, Massachusetts-based urology diagnostics firm.
The colon cancer screening test is now covered in-network by the insurance company in Indiana, Ohio, Kentucky, Missouri, and Wisconsin.
Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.
NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.
Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.
In Science this week: review discusses advances in liquid biopsies, and more.